Showing results (1-10 of 121) with videos related to
Sort By:
Pageof 13
Primary Care Diabetes|April 9, 2022
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetesBasem M Mishriky, Doyle M Cummings, James R PowellPrimary Care|May 20, 2022
Diabetes-Related Microvascular Complications - A Practical ApproachBasem M Mishriky, Doyle M Cummings, James R PowellDiabetes, Obesity & Metabolism|October 1, 2020
Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trialsVictor Okunrintemi, Basem M Mishriky, James R Powell, et al.Diabetes Research and Clinical Practice|May 31, 2021
The benefit of GLP-1RA in different age groups in the cardiovascular outcome trialsAhmed M Younes, Basem M Mishriky, James R Powell, et al.Journal of the American Association of Nurse Practitioners|April 14, 2020
Transitioning to non-insulin therapy in a patient receiving high dose insulinBasem M Mishriky, Doyle M Cummings, Carlos E Mendez, et al.Diabetes Research and Clinical Practice|June 11, 2015
The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysisBasem M Mishriky, Doyle M Cummings, Robert J TanenbergDiabetes, Obesity & Metabolism|June 7, 2019
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysisBasem M Mishriky, James R Powell, Jennifer A Wittwer, et al.Postgraduate Medicine|October 11, 2018
Re-examining insulin compared to non-insulin therapies for type 2 diabetes: when in the disease trajectory is insulin preferable?Basem M Mishriky, Doyle M Cummings, Robert Tanenberg, et al.Journal of Clinical Pharmacology|May 13, 2020
Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic ReviewJarrod L Uhrig, Stephanie O Page, Basem M Mishriky, et al.Diabetes, Obesity & Metabolism|February 16, 2024
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world dataBasem M Mishriky, Doyle M Cummings, Yuanyuan Fu, et al.Pageof 13